IFACT: Incidental Findings in Advanced Cancer Therapy

Study summary

The proposed study, IFACT - Incidental Findings in Advanced Cancer Therapy, will address this research gap by examining MSK patients' attitudes, preferences, and information needs regarding incidental findings arising from tumor genomic profiling.

Ask AI to explain this study

Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedSemi-structured interview

The study team can explain what participation involves.

Who it may be forBreast Cancer · Colorectal Cancer

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Feb 13, 2023 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Memorial Sloan Kettering Cancer Center

Study sponsor

Study overview

What this study is about

Purpose: Not specified
Study type: Observational
Phase: Not applicable
Sponsor: Memorial Sloan Kettering Cancer Center
Interventions being studied: Behavioral: Semi-structured interview

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Treatment approach

Supportive or behavioral care→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Part 1:
Patient enrolled on MSK protocol #12-245
Living patient age 18 or older
Patient diagnosed with breast cancer, colorectal cancer, bladder cancer, or lung cancer
Patient residing in New York metro-area Part 2:
Living patient age 18 or older
Consented to Part C of IRB#12-245 and has received results regardless if thereir was a pathogenic variant
Patient diagnosed with cancer type approved for IRB#12-245 Part C (which are currently breast cancer, gynecological cancer, prostate cancer, and GU non-prostate cancer)breast cancer, colorectal cancer, bladder cancer, or lung cancer
Patient residing in New York metro-area

Reasons someone may not be able to joinExclusion criteria

for Part 1 and 2:
Non-English speakers because we do not have the resources to conduct and translate the interviews into other languages.
Patient unwilling or unable to provide informed consent.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Memorial Sloan Kettering Cancer CenterNew York, New York

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Feb 13, 2023. Always confirm current availability with the study team.

View original record ↗